GlassScriptPhysician profile
Dayoung Ko
NPI 1336601822
$4,720.65
in general payments reported to CMS, 2019-2025
26 companies · $2,530 in 2025
The $2,530 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $484 · 2024: $1,707 · 2025: $2,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,443 · Education: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,442.66 |
| Education | $277.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $614.16 | 2023-2025 | |
| Janssen Biotech, INC. | $611.04 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Sun Pharmaceutical Industries INC. | $481.86 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $472.64 | 2023-2025 | Sotyktu |
| Dermavant Sciences, INC. | $338.85 | 2024 | Vtama |
| Galderma Laboratories, L.P. | $309.59 | 2024-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $289.71 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $219.77 | 2025 | |
| Arcutis Biotherapeutics, INC. | $182.51 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $155.76 | 2023-2025 | |
| Amgen INC. | $142.58 | 2023-2024 | Otezla |
| Incyte Corporation | $130.90 | 2024-2025 | Opzelura |
| Pfizer INC. | $128.76 | 2023-2025 | |
| Organon LLC | $113.82 | 2024-2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $91.91 | 2024-2025 | Dupixent, Libtayo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $71.72 | 2023-2025 | Bimzelx, Cimzia |
| Biofrontera INC. | $59.63 | 2024-2025 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.48 | 2023-2024 | Spevigo |
| Mayne Pharma Commercial LLC | $45.10 | 2023-2025 | |
| Leo Pharma INC. | $39.20 | 2025 | Anzupgo, Adbry |
| Cipher Pharmaceuticals US LLC | $34.89 | 2025 | Spinosad, Natroba |
| Almirall LLC | $32.96 | 2025 | Klisyri |
| Revance Therapeutics, INC. | $29.41 | 2025 | |
| Organogenesis INC. | $23.74 | 2025 | Cygnus Dual |
| Kyowa Kirin, INC. | $21.41 | 2024 | Poteligeo |
| Botanix Sb INC | $19.25 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dayoung Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.